InsiderSignal.AI

InsiderSignal.ai

NTRA - Natera, Inc.

Insider Sale by Moshkevich Solomon (Pres, CLINICALDIAGNOSTICS)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

4 days ago, Moshkevich Solomon, serving as Pres, CLINICALDIAGNOSTICS at Natera, Inc. (NTRA), sold 2,182 shares at $204.10 per share, for a total transaction value of $445,341.00. Following this transaction, Moshkevich Solomon now holds 145,700 shares of NTRA.

This sale represents a 1.00% decrease in Moshkevich Solomon's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Monday, April 27, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, April 29, 2026, 2 days after the trade was made.

Natera, Inc. operates in the HEALTHCARE sector, specifically within the DIAGNOSTICS & RESEARCH industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Moshkevich Solomon

Moshkevich Solomon

Pres, CLINICALDIAGNOSTICS

Solomon Moshkevich is the President of Clinical Diagnostics at Natera, Inc., a global leader in cell-free DNA testing[[1]](https://investor.natera.com/news/news-details/2023/Natera-Announces-Senior-Leadership-Appointments/default.aspx). He joined Natera in 2011 and has been instrumental in developing and commercializing the company's cell-free DNA product portfolio, including Panorama, Prospera, and Signatera[[1]](https://investor.natera.com/news/news-details/2023/Natera-Announces-Senior-Leadership-Appointments/default.aspx). Prior to his current role, Moshkevich served as general manager of oncology beginning in 2019, overseeing significant expansion of Signatera, Natera's molecular residual disease test, and leading efforts to achieve Medicare coverage across multiple cancer types[[1]](https://investor.natera.com/news/news-details/2023/Natera-Announces-Senior-Leadership-Appointments/default.aspx). He has also been actively involved in advancing the company's use of artificial intelligence and machine learning, collaborating with clinical researchers to develop AI-assisted tools for extracting and visualizing cancer patient data[[2]](https://oncodaily.com/voices/solomon-moshkevich-438810). Moshkevich began his career as a management consultant at Bain & Company in New York before transitioning to private equity with the investment team at Parthenon Capital in Boston[[1]](https://investor.natera.com/news/news-details/2023/Natera-Announces-Senior-Leadership-Appointments/default.aspx). He holds a B.A. in economics and mathematics from Columbia University, which he completed summa cum laude, and an M.B.A. from Stanford University[[1]](https://investor.natera.com/news/news-details/2023/Natera-Announces-Senior-Leadership-Appointments/default.aspx). As of January 2026, Moshkevich directly owned 123,499 shares of Natera common stock[[3]](https://www.investing.com/news/insider-trading-news/natera-inc-president-moshkevich-sells-675k-in-stock-93CH-4433882).

View full insider profile →

Trade Price

$204.10

Quantity

2,182

Total Value

$445,341.00

Shares Owned

145,700

Trade Date

Monday, April 27, 2026

4 days ago

SEC Filing Date

Wednesday, April 29, 2026

Filed 2 days after trade

HEALTHCAREDIAGNOSTICS & RESEARCH

Discussion

Sign in to join the discussion.
Loading comments…
View news mentioning NTRA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/6057557

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime